This internationally renowned author team provides a unique and thorough analysis and distillation of the endocannabinoid system and its relationship to abdominal obesity, diabetes, and cardiovascular disease. The endocannabinoid system (ECS) plays an important role in cardiometabolic risk, as well as modulating energy balance, feeding behavior, hepatic lipogenesis, and perhaps glucose homeostasis. Evidence suggests that the ECS is overactive in human obesity and dyslipidemia.Critical to the management of cardiometabolic risk, this new, timely book provides practical overviews and management guidance on many important topics, including:

Foreword	p. iii
Preface	p. iv
Contributors	p. ix
Abdominal Obesity, Metabolic Syndrome, and Risk of Cardiovascular Disease	p. 1
Abdominal Obesity in Type 2 Diabetes	p. 11
Obesity and Hypertension	p. 19
Visceral Adiposity, Liver Fat, and Atherogenic Dyslipidemia	p. 27
Visceral Adiposity and Inflammation	p. 33
Abdominal Obesity and Alterations in Haemostasis-Thrombosis	p. 37
Physiological and Metabolic Characteristics of Visceral Adipocytes	p. 49
The Endocrine Function of Adipose Tissue: Implications of Visceral Obesity for Patients With Cardiometabolic Risk	p. 55
Free Fatty Acid Metabolism in Visceral Obesity	p. 69
Animal Models of Visceral Obesity	p. 75
Insulin Sensitivity and Visceral Adiposity: Effects of Rimonabant	p. 81
Physical Activity in the Management of Visceral Obesity and Related Cardiometabolic Risk	p. 89
Can We Change the Lifestyle of High-Risk Patients? Lessons from the Prevention of Diabetes Trials	p. 105
Can We Change the Body Fat Distribution Phenotype? Lessons from PPAR[gamma] Agonists	p. 111
Is There an Optimal Diet for the Management of Abdominal Obesity and Related Cardiometabolic Risk	p. 117
The EC System and Central Control of Energy Balance-The Hypothalamus	p. 123
The EC System and Central Control of Energy Balance: The Nucleus Accumbens	p. 129
The EC System and the HPA Axis	p. 137
The EC System and Gut-Brain Interactions Relevant to Satiety	p. 141
The Endogenous Cannabinoid System in the Gastrointestinal Tract	p. 147
The EC System in the Adipose Tissue and Endocrine Pancreas	p. 153
The EC System in the Immune System and the Inflammatory Response	p. 163
The Endocannabinoid System in the Liver	p. 173
The Endocannabinoid System and Cardiovascular Disease	p. 179
The Endocannabinoid System, Energy Expenditure, and Thermogenesis	p. 185
Effects of Dietary Fatty Acids on Endocannabinoid Signaling in the Brain and Peripheral Organs	p. 191
Endocannabinoid Overactivity and Abdominal Obesity	p. 203
CB[subscript 1] Antagonism in the Management of Abdominal Obesity	p. 209
Abdominal Obesity and the Endocannabinoid System CB[subscript 1] Blockade, Insulin Resistance, and Type 2 Diabetes	p. 219
Abdominal Obesity As a Therapeutic Target to Manage the Atherogenic Dyslipidemia and Related Metabolic Abnormalities	p. 227
CB[subscript 1] Blockade and Hypertension	p. 237
Future Developments 1: CB[subscript 1] Blockade for Weight Gain Subsequent to Smoking Cessation	p. 247
Future Developments 2: Cannabinoid CB[subscript 1] Receptor Blockade in Weight Gain Subsequent to Psychiatric Disorder Treatment	p. 253
Index	p. 261
Table of Contents provided by Ingram. All Rights Reserved.

Supplemental Materials

What is included with this book?

The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.

The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.